Trial intelligence / Profile preview

Pemigatinib monotherapy for recurrent glioma with FGFR alterations

ChiCTR2300072589Phase 2Recruiting

Sponsor
Beijing Sanbo Brain Hospital
Start
Jun 2023
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of pemigatinib in glioma, sponsored by Beijing Sanbo Brain Hospital. Primary endpoint: objective response rate. Started Jun 2023; status: recruiting.

02

Drugs

pemigatinib
03

Conditions

glioma

Beyond the preview

Go deeper on ChiCTR2300072589.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2300072589.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call